论文部分内容阅读
目的观察信必可(布地奈德/福莫特罗粉吸入剂)联合噻托溴铵治疗中重度稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法将150例中重度稳定期COPD患者随机分为A、B、C组各50例。3组患者均给予一般性综合治疗措施,在此基础上A组给予信必可吸入治疗,B组患者给予噻托溴铵吸入治疗,C组给予信必可联合噻托溴铵吸入治疗。比较3组患者治疗前后第1秒用力呼气容积(FEV1),6min步行距离(6-MWD)、圣乔治呼吸问卷得分(SGRQ)变化。结果治疗3个月后,3组FEV1和6-MWD均较治疗前有所增加,SGRQ得分较治疗前有所降低,差异均有统计学意义(P<0.05);且C组患者FEV1和6-MWD均大于A组和B组,SGRQ得分小于A组和B组,差异均有统计学意义(P<0.05)。结论信必可联合噻托溴铵较两药单独使用可明显改善中重度稳定期COPD患者的肺功能和生活质量。
Objective To observe the clinical efficacy of xinbo (budesonide / formoterol powder inhaler) combined with tiotropium in the treatment of moderate-severe chronic obstructive pulmonary disease (COPD). Methods 150 patients with moderate to severe stable COPD were randomly divided into A, B, C group of 50 cases. Three groups of patients were given general comprehensive treatment measures, on the basis of which group A to be given to the letter will be inhalable treatment, patients in group B were treated with inhalation of tiotropium, C group was given letter will be combined with tiotropium inhalation therapy. The FEV1, 6-minute walking distance (6-MWD) and St. George’s Respiratory Questionnaire score (SGRQ) were compared between the three groups before and after treatment. Results After 3 months of treatment, the FEV1 and 6-MWD in three groups increased compared with that before treatment, and the SGRQ scores were lower than those before treatment (all P <0.05). The FEV1 and 6 -MWD were greater than those in group A and group B, and SGRQ scores were lower than those in group A and group B (P <0.05). Conclusion The combination of tiotropium and tiotropium compared with the two drugs alone can significantly improve the lung function and quality of life of moderate-severe stable COPD patients.